Abstract:Programmed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) inhibitors provide an evolution in the field of cancer therapy. This results in unprecedented rates of long-lasting tumor responses, once cancer patients respond to PD1/PD-L1 inhibitors. However, the response rate of most cancers is not greater than 30%, which results in a limited therapeutic efficacy. Therefore, the increase of the therapeutic efficacy of PD1/PD-L1 inhibitors is of utmost importance. Hence, this study demonstrated that the sustained increase of tumor PD-L1 levels induced by long-tumor retaining cisplatin (Cis) nanoparticles improved the therapeutic outcomes of PD1/PD-L1 inhibitors. Cis-loaded poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticle (Cisplatin nanoparticle, P-Cis) caused tumor PD-L1 overexpression in a time dependent manner in vitro and amplified tumor PD-L1 signals at 72 h post treatment in vivo. Synergistic tumor inhibition was achieved when P-Cis was combined with PD1/PD-L1 inhibitors, such as BMS-202 and anti-PD1 antibody (aPD1), and a significantly superior tumor inhibition rate was observed in the combination group (P-Cis plus aPD1). In addition, when mice were treated with a single dose of P-Cis plus aPD1, its synergistic anti-tumor effect was much stronger than that of a single dose of Cis plus aPD1, as their Q values were 1.15 and 1.05 in the Lewis lung carcinoma (LLC) tumor model, and 1.92 and 0.95 in the B16F10 tumor model, respectively. The single dose of P-Cis could increase tumor PD-L1 expression at 72 h post injection, while a single-dose of Cis did not, thus the sustained tumor PD-L1 overexpression induced by P-Cis was essential for enhancing aPD1 therapy. The sustained tumor PD-L1 overexpression highlighted the involvement of PD1/PD-L1 pathway in tumor cell proliferation and CD8+ T cell weakening and increased the role and possibility of PD1/PD-L1 inhibitors to block the PD1/PD-L1 pathway. Collectively, this study identified a potential clinical treatment with P-Cis plus PD1/PD-L1 inhibitors.Statement of significanceProgrammed cell death protein 1 (PD1)/programmed death-ligand 1 (PD-L1) inhibitors provide an evolution in the field of cancer therapy. However, the response rate of most cancers is not greater than 30%, which results in a limited therapeutic efficacy. Therefore, the increase of the therapeutic efficacy of PD1/PD-L1 inhibitors is of utmost importance. Here, Cisplatin (Cis) loaded poly(L-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticle (P-Cis) is found to improve the therapeutic outcomes of PD1/PD-L1 inhibitors via sustained increase of tumor PD-L1 levels, and P-Cis possesses stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug. This identifies a potential clinical treatment with P-Cis plus PD1/PD-L1 inhibitors.

Anti-PD-L1 checkpoint inhibitor combined with nanocarrier-mediated cisplatin codelivery system for effective treatment of pancreatic cancer

Construction of Tumor Microenvironment and Redox Responsive Nanocarrier-Mediated Cisplatin Co-Delivery System for Effective Chemotherapy to Pancreatic Cancer

Hollow Cu2MoS4 Nanoparticles Loaded with Immune Checkpoint Inhibitors Reshape the Tumor Microenvironment to Enhance Immunotherapy for Pancreatic Cancer.

A Nanodrug Simultaneously Inhibits Pancreatic Stellate Cell Activation and Regulatory T Cell Infiltration to Promote the Immunotherapy of Pancreatic Cancer.

Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug

PD-1 Blockade for Improving the Antitumor Efficiency of Polymer-Doxorubicin Nanoprodrug.

Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and Ph Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy

Anti-Pd-1 Therapy Combined With Chemotherapy In Patients With Advanced Pancreas Cancer In A Real-World Clinical Setting.

Co-inhibition of the TGF-β Pathway and the PD-L1 Checkpoint by Ph-Responsive Clustered Nanoparticles for Pancreatic Cancer Microenvironment Regulation and Anti-Tumor Immunotherapy.

Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex

Microneedles loaded with anti-PD-1–cisplatin nanoparticles for synergistic cancer immuno-chemotherapy

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1

Nano-Econazole Enhanced PD-L1 Checkpoint Blockade for Synergistic Antitumor Immunotherapy Against Pancreatic Ductal Adenocarcinoma

Ratiometrically Designed Nanocarrier to Impact Major Cancer Pathways for Effective Pancreatic Cancer Treatment

Multistage Cooperative Nanodrug Combined with PD-L1 for Enhancing Antitumor Chemoimmunotherapy

Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation

Terminating the Criminal Collaboration in Pancreatic Cancer: Nanoparticle-based Synergistic Therapy for Overcoming Fibroblast-Induced Drug Resistance

Liposomal Co-Delivery System Encapsulating Celastrol and Paclitaxel Displays Highly Enhanced Efficiency and Low Toxicity Against Pancreatic Cancer

Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.

Encapsulation of Platinum Prodrugs into PC7A Polymeric Nanoparticles Combined with Immune Checkpoint Inhibitors for Therapeutically Enhanced Multimodal Chemotherapy and Immunotherapy by Activation of the STING Pathway